EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB

View source ↗

Summary

EMA authorised Brilique (ticagrelor) for use in acute coronary syndrome and peripheral vascular disease, with AstraZeneca AB as the marketing authorisation hold…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Peripheral Vascular Disease

Drugs mentioned

• Brilique (ticagrelor)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Acute Coronary Syndrome. MAH: AstraZeneca AB. Decision date: 19/02/2026